Division of Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
J Virol. 2011 Jan;85(1):315-23. doi: 10.1128/JVI.01597-10. Epub 2010 Oct 20.
The innate immune pathways that contribute to the potent immunogenicity of recombinant adenovirus (rAd) vaccine vectors remain largely undefined. Previous studies assessing innate immunity triggered by vaccine vectors have largely focused on in vitro studies involving antigen-presenting cells and on early in vivo inflammatory responses. Here, we systematically explore the Toll-like receptor (TLR) signaling requirements for the generation of cellular immune responses by intramuscular immunization with common and alternative serotype rAd vectors in mice. Antigen-specific CD8(+) T-lymphocyte responses elicited by these rAd vectors were significantly diminished in MyD88(-/-) mice but not in TRIF(-/-) or TLR3(-/-) mice, suggesting the importance of MyD88-dependent TLR signaling. However, the absence of each individual TLR resulted in minimal to no effect on vaccine-elicited cellular immune responses. Moreover, responses were not diminished in IL-1R(-/-) or IL-18R(-/-) mice. These data suggest that rAd vectors engage multiple MyD88-dependent signaling pathways, none of which are individually critical; rather, they are integrated to contribute to the potent immunogenicity of rAd vectors. Stimulation of multiple innate immune mechanisms may prove a generalizable property of potent vaccines, and this strategy could be harnessed in the development of next-generation vaccine vectors and adjuvants.
固有免疫途径有助于重组腺病毒 (rAd) 疫苗载体产生强大的免疫原性,但这些途径在很大程度上仍未得到明确。以前评估疫苗载体引发固有免疫的研究主要集中在涉及抗原呈递细胞的体外研究和早期的体内炎症反应上。在这里,我们系统地研究了 Toll 样受体 (TLR) 信号通路在肌内免疫接种常见和替代血清型 rAd 载体时产生细胞免疫反应的需求。在 MyD88(-/-) 小鼠中,这些 rAd 载体引发的抗原特异性 CD8(+) T 淋巴细胞反应明显减少,但在 TRIF(-/-)或 TLR3(-/-)小鼠中没有减少,这表明 MyD88 依赖性 TLR 信号的重要性。然而,每种 TLR 的缺失对疫苗引起的细胞免疫反应的影响最小或没有影响。此外,在 IL-1R(-/-)或 IL-18R(-/-)小鼠中,反应也没有减少。这些数据表明,rAd 载体与多种 MyD88 依赖性信号通路相互作用,其中没有一种是单独关键的;相反,它们被整合起来,有助于 rAd 载体的强大免疫原性。刺激多种固有免疫机制可能是有效疫苗的一种普遍特性,这种策略可以在下一代疫苗载体和佐剂的开发中得到利用。